Moreover, SHP2 has been defined as a downstream effector of numerous RTKs, and SHP2 blockade may be a possible mechanism causing RTK activation, resulting in the development of acquired resistance to sorafenib in HCC (98). Here, PTPN11 is linked to hepatocellular carcinoma.